Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.
Our Vision

A trusted advisor
transforming patients’ lives worldwide
with pioneering molecular diagnostics

The global leader
in precision medicine
Myriad Can Improve Patient Outcomes While Lowering Cost

**Precision Medicine Addressing Healthcare Waste in Markets Totaling ≈$600B in Healthcare Spending**

25% of Healthcare Spending is Waste*  

**TOTAL U.S. SPEND**

- **NEUROSCIENCE**  
  $201B

- **WOMENS HEALTH**  
  $150B

- **ONCOLOGY**  
  $137B

- **AUTOIMMUNE**  
  $100B

**Precision Medicine Can:**

- Find patients early at high risk of disease
- Aid in early diagnosis of diseases where treatment costs are lower
- Identify low risk patients who can forego treatment
- Aid in appropriate therapy selection preventing waste

Expanding Precision Medicine Industry into Blue Ocean Opportunities

Untapped Markets in Neuroscience and Autoimmune Disease Where Myriad is Positioned as the Industry Leader

ONCOLOGY

1.7M new patients diagnosed annually with 15M affected

$137B in U.S. healthcare spending

>25 precision medicine companies

>$40B drug spend 40% response

600,000 deaths in U.S. annually

NEUROSCIENCE

>11M new patients diagnosed annually with >40M affected

$201B in U.S. healthcare spending

3 precision medicine companies

>$60B drug spend 48% response

800,000 deaths in U.S. annually

AUTOIMMUNE

1.3M new patients diagnosed annually with 23M affected

$100B in U.S. healthcare spending

2 precision medicine companies

>$55B drug spend 68% response

250,000 deaths in U.S. annually

Myriad Positioned For Future Leadership in Precision Medicine

Key Attributes Distinguish Myriad From Other Companies in Fragmented Precision Medicine Industry

### Unique Scale
- Revenue of $851M in FY19
- ≈3K employees dedicated to the Myriad mission
- 11 products addressing $15B in U.S. TAM
- > 1M tests in FY19

### Pioneering Science
- Expertise across all three types of biomarkers (DNA, RNA & Proteins)
- Over 1K scientific publications
- Leading data capabilities
- Broad regulatory and clinical trial expertise

### Commercial Breadth
- > 100,000 ordering physicians
- > 700 person field sales force
- Largest managed care organization with 95% of U.S. payers in network
- 143 countries have ordered tests

### Financial Strength
- Only profitable precision medicine company
- Significant cash flow and operating margins
- Strong balance sheet
Myriad’s 4 in 6 Strategy

Answering patients’ 4 most pressing questions

• Will I get a disease?
• Do I have a disease?
• Should I treat this disease?
• How should I treat this disease?

In 6 medical specialties

• Women’s Health
• Neuroscience
• Oncology
• Autoimmune
• Urology
• Dermatology
# Most Attractive Product Pipeline in Diagnostic Industry

11 Products Addressing >$15B of U.S. Market Potential

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>U.S. TAM</th>
<th>KEY QUESTION ANSWERED</th>
<th>DISTRIBUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>myRisk</td>
<td>$2.5B</td>
<td>What is my risk for getting cancer?</td>
<td></td>
</tr>
<tr>
<td>genesight</td>
<td>$10.0B</td>
<td>Does my antidepressant have gene-drug interaction?</td>
<td></td>
</tr>
<tr>
<td>Foresight</td>
<td>$5.0B</td>
<td>Is my child at risk for a genetic condition?</td>
<td></td>
</tr>
<tr>
<td>Vectra</td>
<td>$1.5B</td>
<td>Is my RA under control?</td>
<td></td>
</tr>
<tr>
<td>Prolaris</td>
<td>$0.6B</td>
<td>Do I have an aggressive form of prostate cancer?</td>
<td></td>
</tr>
<tr>
<td>EndoPredict</td>
<td>$0.3B</td>
<td>How aggressive is my breast cancer and how should I treat it?</td>
<td></td>
</tr>
<tr>
<td>MyChoice</td>
<td>$2.5B</td>
<td>Am I a good candidate for a PARP inhibitor?</td>
<td></td>
</tr>
<tr>
<td>myPath</td>
<td>$0.4B</td>
<td>Is this skin lesion melanoma?</td>
<td></td>
</tr>
</tbody>
</table>

Product Distribution:
- Oncology
- Women's Health
- Neuroscience
- Autoimmune
- Urology
- Dermatology
Critical Success Factors to Achieve Strategic Goals

- Expand reimbursement coverage for new products
- Build upon solid hereditary cancer foundation
- Grow new product volume

Strategic Goals:
- $>10\%$ revenue growth
- $7$ products $>$ $50$M
- $>30\%$ operating margin

Expand reimbursement coverage for new products
Grow new product volume
Build upon solid hereditary cancer foundation
Solid Foundation in Hereditary Cancer Market
Growing Volume, Increasing TAM, and Long Term Contracts

Growing Volume
- Market less than 15% penetrated
- 8% CAGR since FY13
- Double digit YoY growth in 1Q FY20

Rational Pricing Outlook
- Long term contracts provide predictable pricing
- Smaller price premium easily justifiable given quality advantages

Market Catalysts
- New indications add 175k patients in last two years
- Pancreatic and prostate CDx indications in FY20; potential for adjuvant breast in FY21
- ASBS/NCCN breast cancer expanded guidelines
Diversification with Rapidly Expanding New Product Volume

75% of Test Volume in FY19 From New Products

New Product Diversification

- 75% of volume in FY19 vs. 1% in FY13
- 153% CAGR FY13-FY19
- FY19 Counsyl acquisition allows entry into high growth prenatal market
- Planned primary care expansion for GeneSight in 2H FY19 expands market opportunity by 60%
New Products Represent $15B U.S. Opportunity

FY19 Revenue

TAM (in $B)

$0.0

$5.0

$10.0

$15.0

U.S. TAM

$5B Reimbursed Addressable Market (RAM)

$10B

Additional Insurance Coverage

Market Penetration

$0.3B
# GeneSight Launch Into Primary Care Market

*New Sales Channel Represents 60% of the Market*

<table>
<thead>
<tr>
<th>Psychiatry Market</th>
<th>Primary Care Market</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major Depressive Disorder Patients</td>
<td>1M</td>
</tr>
<tr>
<td>Generalized Anxiety Disorder Patients</td>
<td>1M</td>
</tr>
<tr>
<td>Sales Team</td>
<td>165 sales reps</td>
</tr>
<tr>
<td>Reimbursement</td>
<td>Medicare, UnitedHealthcare, CareFirst, 3 major employers</td>
</tr>
</tbody>
</table>
FY19 Test Volume Fully Reimbursed = $1.5B in Revenue

Incremental Revenue Would Drive Operating Margins >40%

$0 $500 $1,000 $1,500 $2,000

Revenue (millions)

FY19 Actual

• Hereditary Cancer

FY19 Full Reimbursement

• New Products

- >40% operating margins
- >$8.00 in adjusted EPS
- >$600M in FCF
# Increasing Payer Coverage Fuels Growth Potential

*Incremental Reimbursement Could Add >$10B To U.S. TAM*

## Recent Payer Progress

- UnitedHealthcare and CareFirst cover GeneSight
- Kroger becomes first large employer to cover GeneSight – three large self-funded employers now cover the test
- Signed Master Service agreement for GeneSight with large PBM
- Prenatal average risk receives positive tech assessment from BCBS
- NCCN guidelines for Prolaris increase Medicare and commercial coverage to 56%
- myPath Melanoma Medicare coverage

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>Current Coverage</th>
<th>ADDITIONAL OPPORTUNITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>genesight</td>
<td>20%</td>
<td>$8.0B</td>
</tr>
<tr>
<td>Foresight</td>
<td>66%</td>
<td>$0.8B</td>
</tr>
<tr>
<td>Prequel</td>
<td>66%</td>
<td>$0.8B</td>
</tr>
<tr>
<td>Vectra</td>
<td>40%</td>
<td>$0.9B</td>
</tr>
<tr>
<td>Prolaris</td>
<td>56%</td>
<td>$0.3B</td>
</tr>
<tr>
<td>EndoPredict</td>
<td>90%</td>
<td>&lt;$0.1B</td>
</tr>
<tr>
<td>myPath</td>
<td>30%</td>
<td>$0.3B</td>
</tr>
</tbody>
</table>
# Catalysts for Increased Reimbursement Coverage

**Significant Opportunity for Near-Term RAM Expansion**

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>REIMBURSEMENT CATALYSTS</th>
</tr>
</thead>
</table>
| genesight®    | • Medicare final LCD  
|               | • Publication of precision medicine analysis of the GUIDED study  
|               | • Commercial reimbursement decisions  
|               | • PBM agreements  
|               | • Self-funded employer agreements |
| Foresight     | • Expanded carrier screening (ECS) in ACOG and ACMG guidelines  
|               | • Positive payer medical policy for ECS |
| Prequel®      | • Average risk NIPS in ACOG and ACMG guidelines  
|               | • Microdeletions in ACOG and ACMG guidelines; new Prequel microdeletion panel in 2H FY20 |
| Vectra®       | • Payer pilot studies  
|               | • PBM agreements  
|               | • ACR guidelines |
| Prolaris®     | • Medicare dossier for non-favorable intermediate and high-risk patients  
|               | • New utility data showing durability of active surveillance decisions |
| myPath®       | • Recent favorable Medicare LCD |
| myChoice® CDx | • ADLT status established at $4,040  
|               | • Potential first-line ovarian and metastatic breast cancer indications in CY20 |
Uses of Cash

Continued Opportunity to Deploy Capital to Maximize Shareholder Returns

<table>
<thead>
<tr>
<th>USES OF CASH</th>
<th>CURRENT FOCUS</th>
<th>GOAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D</td>
<td>10% of revenue</td>
<td>Invest in new product reimbursement and differentiation</td>
</tr>
<tr>
<td>M&amp;A</td>
<td>Integration of Counsyl</td>
<td>Assess opportunities that fit strategy with potential for near-term accretion</td>
</tr>
<tr>
<td>Debt Repayment</td>
<td>$225M at end of 1Q20</td>
<td>Reduce with excess free cash flow</td>
</tr>
<tr>
<td>Share Repurchase</td>
<td>$124M authorized</td>
<td>$50M ASR completed in 2Q19; continue opportunistic purchases</td>
</tr>
</tbody>
</table>
Myriad: The Investment Thesis

Precision medicine is entering a hyper-growth phase

Molecular diagnostics are the keystone to improving patient outcomes and eliminating wasted spend

Myriad is the global leader in this market

Multiple catalysts can transform earnings

Compelling investment opportunity